Last checked at 16 Jun 2021 13:38
Ap19
FORM 8.3
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013
DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
1. KEY INFORMATION
Name of person dealing (Note 1) | J.P. Morgan Securities LLC |
Company dealt in | Xeris Pharmaceuticals, Inc. |
Class of relevant security to which the dealings being disclosed relate (Note 2) | $0.001 common stock |
Date of dealing | 15 June 2021 |
2. INTERESTS AND SHORT POSITIONS
(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)
| Long | Short | ||||
| Number |
| (%) | Number |
| (%) |
(1) Relevant securities | 3,590,493 5.41
| 972,718 1.47
| ||||
(2) Derivatives (other than options) | 494,157 0.74
|
| ||||
(3) Options and agreements to purchase/sell |
|
| ||||
Total | 4,084,650 6.15
| 972,718 1.47
| ||||
Ap20
1. DEALINGS (Note 4)
(a) Purchases and sales
Purchase/sale |
Number of relevant securities |
Price per unit (USD)
(Note 5) |
Sale (Borrow Return)
Purchase (Loan Return)
Purchases Purchases Purchases Purchases Purchases Purchases Purchases Purchases Purchases Purchases Purchases Purchases Purchases Purchases Purchases Purchases Purchases Purchases Purchases Purchases Purchases Purchases Purchases Purchases Purchases Purchases Purchases Purchases Purchases Purchases Purchases Purchases Purchases Purchases Purchases Purchases Purchases Purchases Purchases Purchases Purchases Purchases Purchases Purchases Purchases Purchases Purchases Purchases Purchases Purchases Purchases Purchases Purchases Purchases Purchases Purchases Purchases Purchases Purchases Purchases Purchases Purchases Purchases Purchases Purchases Purchases Purchases Purchases
Sales Sales Sales Sales Sales Sales Sales Sales Sales | 64,200
57,900
1 1 689 10 17 2 200 2 27 30 30 2 9 1 15 6 20 9,517 38 649 21 10 18 12 13,917 7 27,069 200 12 2,691 2 3,769 2,212 2 27 1 32 2,144 103 2 2 1,500 2 6 8 76 32 8 2 16 909 2 22 8 48 115 8 7 20 3 3 16 29 9 1 4 7 204
100 3,192 27,069 400 103 111 100 100 404 | N/A
N/A
4.3700 USD 4.3300 USD 4.3173 USD 4.3110 USD 4.3088 USD 4.2900 USD 4.2800 USD 4.2700 USD 4.2515 USD 4.2413 USD 4.2360 USD 4.2200 USD 4.2100 USD 4.2000 USD 4.1940 USD 4.1725 USD 4.1690 USD 4.1642 USD 4.1600 USD 4.1575 USD 4.1570 USD 4.1500 USD 4.1494 USD 4.1425 USD 4.1400 USD 4.1300 USD 4.1247 USD 4.1200 USD 4.1042 USD 4.0891 USD 4.0800 USD 4.0796 USD 4.0751 USD 4.0700 USD 4.0693 USD 4.0600 USD 4.0594 USD 4.0560 USD 4.0535 USD 4.0500 USD 4.0400 USD 4.0313 USD 4.0300 USD 4.0233 USD 4.0225 USD 4.0200 USD 4.0178 USD 4.0063 USD 3.9900 USD 3.9880 USD 3.9800 USD 3.9750 USD 3.9700 USD 3.9650 USD 3.9615 USD 3.9600 USD 3.9525 USD 3.9500 USD 3.9495 USD 3.9433 USD 3.9400 USD 3.9369 USD 3.9364 USD 3.9333 USD 3.9300 USD 3.9200 USD 3.9186 USD 3.9000 USD
4.2800 USD 4.1400 USD 4.1247 USD 4.1200 USD 4.0535 USD 4.0200 USD 3.9600 USD 3.9100 USD 3.9000 USD |
(b) Derivatives transactions (other than options transactions)
Product name, e.g. CFD | Nature of transaction (Note 6) | Number of relevant securities (Note 7) | Price per unit (USD) (Note 5) |
Equity Swap | Decrease Long | 103 27,069 | 4.0535 USD 4.1247 USD |
(c) Options transactions in respect of existing relevant securities
(i) Writing, selling, purchasing or varying
Product name, e.g. call option | Writing, selling, purchasing, varying etc. | Number of securities to which the option relates (Note 7) | Exercise price | Type, e.g. American, European etc. | Expiry date | Option money paid/received per unit (Note 5) |
|
|
|
|
|
|
|
(ii) Exercising
Product name, e.g. call option | Number of securities | Exercise price per unit (Note 5) |
|
|
|
(d) Other dealings (including transactions in respect of new securities) (Note 4)
Nature of transaction (Note 8) | Details | Price per unit (if applicable) (Note 5) |
|
|
|
Ap21
2. OTHER INFORMATION
Agreements, arrangements or understandings relating to options or derivatives
Full details of any agreement, arrangement or understanding between the person disclosing and
any other person relating to the voting rights of any relevant securities under any option referred to
on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to
which any derivative referred to on this form is referenced. If none, this should be stated.
None
Is a Supplemental Form 8 attached? (Note 9) NO
Date of disclosure | 16 June 2021 |
Contact name | Alwyn Basch |
Telephone number | 0207 742 7407 |
If a connected EFM, name of offeree/offeror with which connected | N/A |
If a connected EFM, state nature of connection (Note 10) | N/A |